Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.

Seung-Cheol Shim,Ljubinka Božić Majstorović,Alfredo Berrocal Kasay,Elias Chalouhi El-Khouri,Fedra Irazoque Palazuelos,Francisco Fidencio Cons-Molina,Francisco G. Medina-Rodriguez,Pedro Miranda,Pavel Shesternya,Jose Chavez-Corrales,Piotr Wiland,Sławomir Jeka,Olena Garmish,Paweł Hrycaj,Natalia Fomina,Won Park,Chang-Hee Suh,Sang Joon Lee,Sung-Young Lee,Yun Ju Bae,Dae-Hyun Yoo

Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial.

2019

Objective To evaluate the efficacy and safety of CT-P10, a rituximab biosimilar after a single switch, during a multinational, randomized, double-blind Phase 3 trial involving patients with RA.

Keywords:

Diabetes mellitus
Physical therapy
Medicine
Rheumatoid arthritis
Rituximab
Internal medicine
Biosimilar
Rheumatology
Immunogenicity
Pharmacodynamics
Quality of life
Response rate (survey)
Surrogate endpoint

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations